​

Nektar Therapeutics Ownership | Who Owns Nektar Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Nektar Therapeutics Ownership Summary

Nektar Therapeutics is owned by 14.57% institutional investors, 0.84% insiders, and 84.59% retail investors. Blackrock is the largest institutional shareholder, holding 7.78% of NKTR shares. Eventide Healthcare & Life Sciences I is the top mutual fund, with 3.57% of its assets in Nektar Therapeutics shares.

NKTR Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockNektar Therapeutics14.57%0.84%84.59%
SectorHealthcare Stocks 488.30%11.08%-399.38%
IndustryBiotech Stocks 307.10%11.11%-218.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock15.16M7.78%$18.79M
Altium capital management lp3.00M1.43%$2.79M
Millennium management2.29M1.09%$1.56M
Eversept partners, lp115.00K0.82%$2.97M
Morgan stanley1.47M0.76%$1.83M
Simplify asset management87.17K0.62%$4.96M
Moody aldrich partners73.72K0.52%$4.19M
Aqr capital management833.26K0.40%$774.93K
Stonepine capital management50.20K0.36%$1.30M
Goldman sachs group727.39K0.35%$676.47K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Allostery investments lp4.00K1.32%$103.36K
Stonepine capital management50.20K1.27%$1.30M
Moody aldrich partners73.72K0.80%$4.19M
Altium capital management lp3.00M0.79%$2.79M
Eversept partners, lp115.00K0.27%$2.97M
Palumbo wealth management23.77K0.19%$614.27K
Gainplan5.04K0.12%$286.49K
Eam investors24.16K0.09%$624.19K
Simplify asset management87.17K0.09%$4.96M
Dafna capital management10.00K0.07%$258.40K

Top Buyers

HolderShares% AssetsChange
Blackrock15.16M0.00%9.28M
Altium capital management lp3.00M0.79%2.99M
Morgan stanley1.47M0.00%1.30M
Aqr capital management833.26K0.00%331.67K
Bank of america corp /de/182.04K-139.79K

Top Sellers

HolderShares% AssetsChange
Blackrock funding, inc. /de---15.71M
Vanguard group---12.31M
Samlyn capital---9.67M
Nantahala capital management---7.79M
Acadian asset management---7.30M

New Positions

HolderShares% AssetsChangeValue
Eversept partners, lp115.00K0.27%115.00K$2.97M
Stonepine capital management50.20K1.27%50.20K$1.30M
Eam investors24.16K0.09%24.16K$624.19K
Palumbo wealth management23.77K0.19%23.77K$614.27K
Marshall wace, llp14.20K0.00%14.20K$366.93K

Sold Out

HolderChange
Cornerstone planning group-5.00
Assetmark-22.00
Cubist systematic strategies-40.00
Steward partners investment advisory-40.00
Capital performance advisors llp-66.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202537-77.30%2,048,084-98.35%140.42%10-86.49%27-44.90%
Mar 31, 20258-94.59%15,114,671-88.63%70.18%2-97.14%4-88.89%
Dec 31, 2024137-2.84%129,034,595-8.31%611.36%646.67%33-8.33%
Sep 30, 20241413.68%140,729,0353.96%671.39%61-15.28%365.88%
Jun 30, 202413610.57%135,373,25519.87%692.07%7294.59%34-29.17%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Eventide Healthcare & Life Sciences I6.65M3.57%-
Vanguard US Total Market Shares ETF5.72M3.08%-
Vanguard Total Stock Mkt Idx Inv524.03K2.93%142.38K
iShares Russell 2000 ETF4.62M2.48%-
PRIMECAP Odyssey Aggressive Growth188.82K1.09%-42.10K
iShares Russell 2000 Value ETF1.66M0.89%-
Fidelity Small Cap Index1.83M0.70%-
Vanguard Institutional Extnd Mkt Idx Tr120.87K0.68%-52.78K
Vanguard Strategic Equity Inv101.14K0.58%10.00
Emerald Growth A90.20K0.50%90.20K

Recent Insider Transactions

DateNameRoleActivityValue
Sep 09, 2025ROBIN HOWARD W President & CEOSell$102.39K
Sep 09, 2025ROBIN HOWARD W President & CEOSell$58.30K
Sep 09, 2025ROBIN HOWARD W President & CEOSell$94.84K
Sep 09, 2025ROBIN HOWARD W President & CEOSell$55.69K
Sep 04, 2025Zalevsky Jonathan Chief R&D OfficerSell$14.52K

Insider Transactions Trends

DateBuySell
2025 Q3-20
2025 Q2-3
2025 Q1-3
2024 Q4-8
2024 Q3-3

NKTR Ownership FAQ

Who Owns Nektar Therapeutics?

Nektar Therapeutics shareholders are primarily institutional investors at 14.57%, followed by 0.84% insiders and 84.59% retail investors. The average institutional ownership in Nektar Therapeutics's industry, Biotech Stocks , is 307.10%, which Nektar Therapeutics falls below.

Who owns the most shares of Nektar Therapeutics?

Nektar Therapeutics’s largest shareholders are Blackrock (15.16M shares, 7.78%), Altium capital management lp (3M shares, 1.43%), and Millennium management (2.29M shares, 1.09%). Together, they hold 10.30% of Nektar Therapeutics’s total shares outstanding.

Does Blackrock own Nektar Therapeutics?

Yes, BlackRock owns 7.78% of Nektar Therapeutics, totaling 15.16M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 18.79M$. In the last quarter, BlackRock increased its holdings by 9.28M shares, a 157.82% change.

Who is Nektar Therapeutics’s biggest shareholder by percentage of total assets invested?

Allostery investments lp is Nektar Therapeutics’s biggest shareholder by percentage of total assets invested, with 1.32% of its assets in 4K Nektar Therapeutics shares, valued at 103.36K$.

Who is the top mutual fund holder of Nektar Therapeutics shares?

Eventide Healthcare & Life Sciences I is the top mutual fund holder of Nektar Therapeutics shares, with 3.57% of its total shares outstanding invested in 6.65M Nektar Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools